Estimated coverage to address financial barriers to HIV preexposure prophylaxis among persons with indications for its use, United States, 2015
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Estimated coverage to address financial barriers to HIV preexposure prophylaxis among persons with indications for its use, United States, 2015

Filetype[PDF-409.89 KB]


  • English
    • Details Supporting Files You May Also Like

    Details:

    • Alternative Title:
      J Acquir Immune Defic Syndr
    • Personal Author:
    • Description:
      Background

      An estimated 1.2 million American adults engage in sexual and drug use behaviors that place them at significant risk of acquiring HIV infection. Engagement in health care for the provision of daily oral antiretroviral medication as preexposure prophylaxis (PrEP), when clinically indicated, could substantially reduce the number of new HIV infections in these persons. However, resources to cover the financial cost of PrEP care is an anticipated barrier for many of the populations with high numbers of new HIV infections.

      Methods

      Using nationally representative data, we estimated the current national met and unmet need for financial assistance with covering the cost of PrEP medication, clinical visits, and laboratory costs among adults with indications for its use, overall and by transmission risk population.

      Results

      This study found that, of the 1.2 million adults estimated to have indications for PrEP use, <1% (∼7,300) are in need of financial assistance for both PrEP medication and clinical care, at an estimated annual cost of $89 million. An additional 7% (∼86,300) are in need of financial assistance only for PrEP clinical care at an estimated annual cost of $119 million.

      Conclusion

      This information on PrEP care costs, insurance coverage, and unmet financial need among persons in key HIV transmission risk subpopulations can inform policy makers at all levels as they consider how to address remaining financial barriers to the use of PrEP and accommodate any changes in eligibility for various insurance and financial assistance programs that may occur in coming years.

    • Subject:
    • Source:
      J Acquir Immune Defic Syndr. 76(5):465-472
    • Pubmed ID:
      28834798
    • Pubmed Central ID:
      PMC5821499
    • Document Type:
      Journal Article
    • Funding:
      CC999999/ImCDC/Intramural CDC HHS/United States
    • Place as Subject:
      United States
    • Collection(s):
      CDC Public Access
    • Main Document Checksum:
    • File Type:

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov